Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/110751
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCallejo Castillo, Àngela-
dc.contributor.authorSedó Cabezón, Lara-
dc.contributor.authorDoménech Juan, Ivan-
dc.contributor.authorLlorens i Baucells, Jordi-
dc.date.accessioned2017-05-10T10:19:33Z-
dc.date.available2017-05-10T10:19:33Z-
dc.date.issued2015-07-15-
dc.identifier.issn2305-6304-
dc.identifier.urihttp://hdl.handle.net/2445/110751-
dc.description.abstractCisplatin is a highly effective chemotherapeutic agent that is widely used to treat solid organ malignancies. However, serious side effects have been associated with its use, such as bilateral, progressive, irreversible, dose-dependent neurosensory hearing loss. Current evidence indicates that cisplatin triggers the production of reactive oxygen species in target tissues in the inner ear. A variety of agents that protect against cisplatin-induced ototoxicity have been successfully tested in cell culture and animal models. However, many of them interfere with the therapeutic effect of cisplatin, and therefore are not suitable for systemic administration in clinical practice. Consequently, local administration strategies, namely intratympanic adminis- tration, have been developed to achieve otoprotection, without reducing the antitumoral effect of cisplatin. While a considerable amount of pre-clinical information is available, clinical data on treatments to prevent cisplatin ototoxicity are only just beginning to appear. This review summarizes clinical and experimental studies of cisplatin ototoxicity, and focuses on understanding its toxicity mechanisms, clinical repercussions and prevention strategies.-
dc.format.extent26 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/toxics3030268-
dc.relation.ispartofToxics, 2015, vol. 3, p. 268-293-
dc.relation.urihttps://doi.org/10.3390/toxics3030268-
dc.rightscc-by (c) Callejo, Angela et al., 2015-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCisplatí-
dc.subject.classificationMedicaments antineoplàstics-
dc.subject.classificationEfectes secundaris dels medicaments-
dc.subject.classificationToxicitat dels medicaments-
dc.subject.classificationTrastorns auditius-
dc.subject.classificationSordesa-
dc.subject.classificationRessenyes sistemàtiques (Investigació mèdica)-
dc.subject.otherCisplatin-
dc.subject.otherAntineoplastic agents-
dc.subject.otherDrug side effects-
dc.subject.otherDrug toxicity-
dc.subject.otherHearing disorders-
dc.subject.otherDeafness-
dc.subject.otherSystematic reviews (Medical research)-
dc.titleCisplatin-induced ototoxicity: effects, mechanisms and protection strategies-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec655807-
dc.date.updated2017-05-10T10:19:34Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid29051464-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Centres Científics i Tecnològics de la Universitat de Barcelona (CCiTUB))

Files in This Item:
File Description SizeFormat 
655807.pdf574.53 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons